Tesamorelin Phase 4 HIV Body Composition Trial Marked Terminated

A clinical trial involving tesamorelin has been updated with a status change as of May 19, 2026. The study, titled "Body Composition and Adipose Tissue in HIV," is registered as NCT03226821 on ClinicalTrials.gov. It was designated a Phase 4 trial, indicating research conducted after regulatory approval of the compound. The current status listed for this trial is terminated. The registry entry does not provide additional detail in this update regarding the reason for termination. No results, efficacy data, or safety findings were included in this event record. This brief reflects only the status change recorded in the trial registry and does not represent an interpretation of outcomes or trial conduct. Readers interested in the trial's design, sponsor information, or further updates can consult the ClinicalTrials.gov listing directly for the most current record. Tesamorelin remains an approved compound, and this trial update pertains specifically to a Phase 4 post-approval study focused on body composition and adipose tissue changes in an HIV patient population. For general background on tesamorelin, readers can consult the compound overview.